Drugs / AC430
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01287858 Comparator | Nov 2010 → Jun 2011 | rheumatoid arthritis | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AC430 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01287858 ↗ |
| Action | Inhibit | “Tyrosine-protein kinase JAK2 inhibitor” CHEMBL3545241 ↗ |
| Modality | Small molecule | — CHEMBL3545241 ↗ |
| Route | Oral | “AC430 will be administered, orally under fasting conditions” NCT01287858 ↗ |
| Target | JAK2 | “Tyrosine-protein kinase JAK2 inhibitor” CHEMBL3545241 ↗ |